

## SUBJECT INDEX VOLUME-2

<p>Abl kinases ..... 135  in CML therapy ..... 135  in inhibition by intramolecular/intermolecular interactions ..... 135  inhibition of with intermolecular interactions <i>via</i> the C-terminus ..... 143  structure studies of ..... 135</p> <p>Acid sphingomyelinase ..... 129  inhibition of ..... 129</p> <p>Acyl transferases ..... 67  inhibitors of ..... 67</p> <p><math>\beta</math>-Adrenergic signaling ..... 19  release of Ca-ATPase inhibition in response to ..... 19</p> <p>Alzheimer's disease (AD) ..... 311  amyloid-<math>\beta</math> peptide isoforms in ..... 314  anti-amyloid drugs used in ..... 314  BACE1 in ..... 315  beta-amyloid peptide (A<math>\beta</math>) in ..... 312  beta secretase homolog in ..... 315  biological function of amyloid-<math>\beta</math> precursor protein ..... 313  gamma-secretase inhibitors in ..... 318  histopathology of ..... 312  pathology of ..... 311  symptoms of ..... 311</p> <p>Aminopeptidases ..... 67  inhibitors of ..... 67</p> <p>Anti-AChE/ChE inhibitors ..... 252  as pesticides ..... 255  chemical classes of ..... 253  in AD ..... 257  in autonomic neurotransmission dysfunction ..... 256  in myasthenia gravis ..... 256  mechanism of action of ..... 252  mechanism of toxicity of ..... 254  pharmacological properties of ..... 253  structure-activity relationships of ..... 253  therapeutic uses of ..... 256  toxicology of ..... 258  use in weapons ..... 254</p> <p>Antioxidant enzymes ..... 245  regulation/expression of ..... 245</p> <p>Aromatase inhibitors ..... 189  A-ring modifications of ..... 190  B-ring modifications of ..... 191  C-ring modifications of ..... 193  D-ring modifications of ..... 194  development of steroidal based ..... 189</p> <p>Astaxanthin ..... 241  animal studies of ..... 241  cell studies of ..... 241</p> <p>Bacterial bioluminescent enzymes ..... 363  interactions of heavy-atom-containing</p>	<p>molecules with ..... 367  interactions with non-fluorescent compounds ..... 368  non-specific effects of exogenous compounds on ..... 363</p> <p>Bacterial luciferase ..... 364  interactions of exogenous compounds with ..... 364</p> <p>BCR-ABL ..... 136  in etiology of CML ..... 138  in etiology of CML chronic phase ..... 137  inhibition of ..... 138  inhibition by imatinib ..... 141  inhibition by intramolecular interactions ..... 140  inhibitors for ..... 144  novel inhibitors for ..... 140</p> <p>Beta-secretase (BACE) ..... 315  biochemical characterization of ..... 315</p> <p>c-ABL ..... 135  variants of ..... 135</p> <p><i>Caenorhabditis elegans</i> ..... 173  as model organism ..... 175  as study model for animal/human cathepsins/  inhibitors ..... 173  functional analysis of cathepsin Z in ..... 179</p> <p>Cancer ..... 163,353  aminopeptidase A in ..... 356  angiotensin converting enzyme in ..... 356  endothelin axis in ..... 357  JAKS/JAK signaling in ..... 164  neprilysin in ..... 359  renin-angiotensin system in human ..... 354  renin inhibitors in ..... 354  signal transducer/activator of transcription (STAT) in ..... 163  suppressors of JAK signaling in ..... 164</p> <p>Carcinogenic ..... 271</p> <p><math>\beta</math>-Carotene ..... 244  cell/animal studies of ..... 244  human studies of ..... 244  plant extracts of ..... 244</p> <p>Carotenoid ..... 231  modulation of antioxidant enzymes by ..... 231,241  protection in biological systems ..... 231</p> <p>Catalase ..... 3  physiological significance of ..... 12</p> <p>Catecholamines ..... 53</p> <p>Cathepsins ..... 173  in parasites ..... 175  lysosomal type ..... 176  role in cell biology ..... 174</p> <p>Cathepsin B ..... 176  characteristic features of ..... 176</p>
--	---

function of B in parasites .....	177	side effects of .....	377
mammalian type .....	176	specific ECE inhibitors as .....	376
Cathepsin L .....	177	triple ECE/NEP/ACE inhibitors as .....	376
characteristics of .....	177	Endothelin-converting enzyme inhibitors .....	373
function of .....	177	Endothelin system .....	373
in <i>Caenorhabditis elegans</i> .....	177	Enzymes .....	1
Cathepsin Z .....	179	destruction in biological systems .....	4
characteristics of .....	179	in metabolism .....	1
function of .....	179	in nitrite toxicity .....	1
Ceramide-1-phosphate .....	129	Erythrocytes .....	54
Cerebral hypoxia-ischemia .....	222	Erythropoietin .....	54
constitutive NOS (nNOS/eNOS) in .....	222	long-term (2-24 h) regulation by .....	54
iNOS in .....	224	Extracellular matrix .....	306
Chlorophenols .....	387	Farnesylation .....	270
Cholinesterase inhibitors .....	249	direct inhibitors of .....	270
actions at effectors .....	252	Flavonols .....	240
as cognition enhancing drugs .....	249	animal studies of .....	240
as pesticides .....	249,255	cell studies of .....	240
use in weapons .....	249,254	Flavanones .....	240
Chronic myelogenous leukemia (CML) .....	135	animal studies of .....	240
identification of ABL kinase in .....	135	cell studies of .....	240
therapy of .....	143	FMN-oxidoreductase .....	364
Computer-aided drug design .....	311	Gamma-secretase .....	316
applied to beta/gamma secretase inhibitors .....	311	3D-QSAR methods for .....	319
therapy for .....	311	3D-QSAR-CoMFA method for .....	319
Cystatins .....	180	computational chemistry methods to .....	319
as natural inhibitors of cysteine proteases		computational studies applied to .....	322
characteristics .....	180	in pathobiology of Alzheimer's disease .....	316
Cysteine proteases .....	180	molecular docking to .....	320
diagnostic/therapeutic potential of .....	182	role of presenilin proteins to .....	317
functional analysis in .....	181	Glucose transporters .....	305
in cardiovascular diseases .....	183	identification in glomeruli .....	305
in infectious diseases .....	184	in collecting duct .....	308
interaction with .....	180	in normal/diabetic kidneys .....	305
physiological functions of .....	180	in proximal tubules .....	307
Cytochrome P450 superfamily .....	282	in thick ascending limb .....	307
inhibitors of .....	286	role in glomerular glucose metabolism .....	306
D-alanyl-D-alanine carboxypeptidase/transpeptidases		HDAC inhibitors .....	99
(DD-peptidases) .....	70	as differentiating agents for primary	
Diabetic nephropathy .....	308	hepatocytes .....	99
glut1 susceptibility alleles for .....	308	as inhibitors of proliferation/inducers of	
Digitalis-like factors .....	54	differentiation .....	99
Eicosanoid inhibitors .....	73	Heme oxygenase (HO)-1 .....	105
as therapeutic targets for metabolic syndrome		as target for cancer treatment .....	116
related kidney disease .....	73	cytoprotection in organ transplantation .....	115
Endothelin .....	353,373	expression in LPS-induced septic lung injury .....	107
biosynthesis of .....	373	hypoxia-regulated gene expression of .....	114
dual ECE/NEP inhibitors as .....	375	in hepatocyte injury in steatotic liver	
in cancer .....	353	transplants .....	116
isoforms/function of .....	373	in protection of ischemic ARF (IARF) .....	110
receptor classification of .....	374		

in renal injury of IARF .....	113	in multiple myeloma .....	167
in suppression of humoral immune response in		in solid tumors .....	168
allograft transplantation .....	116	role in malignant cell growth/survival .....	165
in xenograft transplantation .....	116	JAK/STAT pathway .....	165
induction in acute liver failure (ALF) .....	108	dysregulation of .....	165
induction in lung injury .....	107	Laccases .....	343
induction in oxidative tissue injuries .....	107	deactivating agents of .....	344
induction in pulmonary arterial hypertension		immobilization/encapsulation of .....	348
(PAH) .....	107	in halides .....	345
induction in sepsis .....	110	in ionic strength .....	347
intestinal site of .....	110	in organic solvents .....	347
overexpression of .....	110	in surfactants .....	348
protection of acute liver injury by .....	112	inhibitors of .....	343
role of free heme in induction of .....	118	$\beta$ -Lactamase .....	69
Hepatocytes .....	94	Leukemia .....	167
isolation of .....	94	JAK-kinase pathways in .....	167
Histone acetylation/deacetylation .....	96	Liver .....	91
of proliferation/differentiation-related genes .....	96	as target organ for toxicity .....	91
Histone deacetylase .....	91	based <i>in vitro</i> models in pharmacotoxicology .....	92
in cell proliferation/differentiation .....	97	Lycopene .....	243
inhibition of .....	91	animal studies of .....	243
role in differentiation therapy for cultured		cell studies of .....	243
primary hepatocytes .....	91	Mesangial cell glut .....	306
HMG-CoA reductase inhibitors .....	261	expression of .....	306
cytoprotective/antiproliferative effects of .....	261	production of .....	306
Ho-1 gene transfer .....	112	Microcystin-LR .....	387
protection of ALI by .....	112	Na/K ATPase .....	37
Hydrogen peroxide .....	1	activity of .....	51
interaction of nitrite with .....	1	alpha subunit of .....	40
Hydrogen peroxide destroying enzymes .....	2	biochemistry of .....	47
in nitrite metabolism/toxic effects .....	2	cell biology of oxygen sensing by .....	47
Hypoxia-ischemia .....	219	FXYP proteins/gamma subunit of .....	46
pathophysiology of brain damage after .....	219	in control of intracellular ROS levels .....	53
IL-10 .....	116	in hypoxia .....	52
in suppression of humoral immune response in		molecular basis of oxygen/redox-sensitivity of .....	38
allograft transplantation .....	116	oxygen/redox-induced modulation of .....	53
Imatinib .....	138	oxygen/redox-induced regulation of .....	37
identification of resistant mutations of .....	141	phosphorylation of $\alpha$ subunit of .....	43
in CML therapy with .....	138	redox-sensitivity of .....	49
problems with therapy of .....	139	structure of .....	38
therapy resistance of .....	138	NAD(P)H .....	364
toxicity/inhibition of .....	139	interactions of exogenous compounds with .....	364
Immature brain .....	220	Neutral sphingomyelinase .....	129
nitric oxide biosynthesis in .....	220	inhibition of .....	131
NO-based therapeutic strategies in .....	225	Newborn hypoxic-ischemic encephalopathy .....	221
particularities of .....	220	NO in .....	221
iNOS .....	224	NF- $\kappa$ B .....	329
regulation of expression of .....	224	as target protein .....	329
role in brain hypoxia-ischemia .....	224	mediated gene products .....	333
JAK kinases .....	165	upstream signals for activation of .....	332
as therapeutic targets in cancer .....	169		
in lymphomas .....	167		

Nitric oxide synthase .....	219	$\delta$ -selective small molecule inhibitors of .....	147
in prevention of hypoxic-ischemic newborn		therapeutic potential of .....	147
brain damage .....	219	Phospholamban (PLB) .....	19
Nitrite .....	9	coil-to-helix transition within .....	19
interaction of heme-containing peroxidases		complex of .....	22
with .....	9	computational modeling of ATPase complex	
role of NO metabolites .....	15	with .....	24
use of specific inhibition of catalase by .....	13	conformational switching/release of inhibition	
Nitrite effect .....	6	of .....	26
on catalase .....	6	dynamic model of Ca-ATPase regulation by .....	25
Nucleotide phosphonates .....	63	high resolution structure of .....	22
		oligomers/monomers of .....	21
		regulation of Ca-ATPase by .....	19
		sites of interaction with Ca-ATPase .....	23
		structure of .....	21
Obesity .....	73	Phosphonate-based inhibitors .....	61
COX regulation in .....	73	targeting enzymes with .....	61
kidney CYP450 in .....	73	Phosphonates .....	62
Obesity related kidney damage .....	75	as isosteric/isopolar mimics of phosphates .....	62
COX-2/CYP450 as therapeutic targets for .....	75	as transition state analogues .....	67
Oxidant stress .....	118	as trypanocidal drugs .....	65
heme metabolites in protection against .....	118	Phosphorus-enzyme covalent bond formation .....	69
Oxidative tissue injury .....	105	Plant isoprenoids .....	270
defense against .....	105	effect on cancer proliferation .....	270
free heme induces acute renal failure in .....	109	Polyphenol .....	231
heme oxygenase isoforms in .....	105	animal studies of .....	239
role of heme oxygenase-1 .....	105	human studies of .....	239
		modulation of antioxidant enzymes by .....	231,232
		protection in biological systems .....	231
P13K inhibitors .....	152	Proteinaceous protease inhibitors .....	199
in acute myeloid leukemia .....	157	actions on immune system disorders .....	206
in hypertension .....	158	against dengue .....	208
therapeutic potential for .....	153	against HCV .....	207
P <sub>450</sub> enzymes .....	281	against HIV .....	207
assessment of inhibitions of .....	296	against SARS .....	207
clinical consequences of inhibition of .....	289	applications of .....	204
HTS inhibition assays of .....	296	as antibacterial/antifungal .....	209
in qualitative pharmacokinetic drug		as anticancer agents .....	210
interactions .....	290	as antiparasitic agents .....	209
<i>in vitro</i> approach to .....	281	as antiviral agents .....	207
inhibition of .....	281	as models for drug design .....	204
P <sub>450</sub> probe substrates .....	295	as natural bioinsecticides .....	204
p65/p50 .....	331	as regulators of hemostasis .....	208
DNA binding mechanism of .....	331	function of .....	199
Papain family .....	174	molecular modeling approaches to .....	204
cysteine proteases of .....	174	multiple functional faces of .....	199
Peroxidases .....	2	structural features of .....	199
Peroxynitrite .....	383	structural/thermodynamic insights on .....	201
Phosphatase inhibitors .....	62	Proteinaceous xylanase inhibitors .....	29
Phosphates .....	61	evolution of .....	29
stable isosteric analogues of .....	61	function <i>in vitro</i> .....	32
tetrahedral transition states of .....	61	function of .....	29
Phosphoinositide 3-kinase .....	147	molecular and 3-D structure of .....	30
genetic manipulation of signaling in mice .....	150	molecular evolution in plant .....	33
in autoimmune disease .....	157	structure of .....	29
in inflammation .....	157	TAXI-1 at .....	30
		XIP-1 at .....	30
		XIP-type inhibitors as .....	32

Renin-angiotensin systems .....	353	SOD as .....	380
in cancer .....	353	extracellular SOD (EC-SOD) as .....	381
Sesquiterpene lactones .....	329	functions of .....	381
as NF- $\kappa$ B activation inhibitors .....	329	in Alzheimer's/Parkinson's diseases .....	394
inhibition of cytokine production by .....	334	in amyotrophic lateral sclerosis (ALS) .....	388
inhibition of NF- $\kappa$ B activation pathways by .....	335	in arthritis .....	393
inhibitory pathways .....	334	in atherosclerosis .....	393
molecular mechanism of .....	334	in autoimmune inflammatory disease .....	391
structure-activity relationship (SAR) of .....	336	in coronary endothelial dysfunction .....	393
suppression of production of inflammatory		in diabetic nephropathy .....	393
mediators by .....	334	in diseases .....	379,388
Sphingomyelinases .....	125	in hyperoxic stress .....	390
activators of .....	129	in liver disease .....	394
ceramides by .....	126	in tumors .....	392
in regulation of cell death/survival .....	125	inhibitors of .....	379
inhibition of .....	129	iron superoxide dismutase (FeSOD) as .....	380
Sphingosine .....	127	localization of .....	380
Sphingosine-1-phosphate .....	127	manganese SOD (Mn-SOD) as .....	380
Statins .....	261	peroxidative activity of .....	382
anticancer effects of .....	271	prevention of thiyl radical formation by .....	383
antioxidative effects of .....	266	structure of .....	380
antiproliferative/immunomodulatory effects in		Tel-ABL (ETV6-ABL) .....	137
nephrological diseases .....	265	Transcriptional regulation .....	96
as inhibitors of farnesylation .....	268	of proliferation/differentiation-related genes .....	96
clinical studies with .....	273	Type 2 diabetes mellitus .....	79
effect on apoptosis .....	269	calcium in .....	79
effect on cyclooxygenase .....	267	cytosolic tyrosine kinase proteins in .....	84
effect on heme oxygenase .....	267	intracellular calcium homeostasis in .....	80
effect on metalloproteinases .....	267	pathogenesis of .....	79
effect on nitric oxide .....	266	receptor tyrosine kinase proteins in .....	82
epidemiology of administration of .....	272	role of tyrosine kinases .....	85
in control of inflammation/endothelial		tyrosine kinases in .....	79
dysfunction .....	262	Tyrosine kinases .....	163
in human diseases .....	273	alterations in human cancer .....	163
in transplantation medicine .....	265	functions of .....	163
intracellular signaling of .....	261	JAK family of .....	163
Superoxide dismutases .....	379	v-Abl .....	136
activity of .....	384	Vegetables .....	245
copper-zinc superoxide dismutase Cu/Zn-		modulation of antioxidant enzymes by .....	245